Axel Hoos

42.0k citations

142 papers · 13.4k indexed · 5 hit papers · h-index 55

Impact in

Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in

Oncology 103
- Cancer Immunotherapy and Biomarkers 64
- CAR-T cell therapy research 45
Immunology 53
- Immunotherapy and Immune Responses 39

Co-authors: Jedd D. Wolchok Steven O’Day Rachel Humphrey F. Stephen Hodi Célèste Lebbé Murray F. Brennan Carlos Cordon‐Cardo Michele Maio
Journals: Journal of Clinical Oncology (37 papers)Annals of Oncology (12 papers)Cancer Research (8 papers)Clinical Cancer Research (5 papers)Nature Reviews Drug Discovery (4 papers)
Partner nations: United States France Germany

In The Last Decade

Axel Hoos

139 papers receiving 13.1k citations

Hit Papers

5 papers align trajectories log scale

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations 2016 · 469 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 Nature Reviews Drug Discovery
2016 Blood
2013 Annals of the New York Academy of Sciences
2009 The Lancet Oncology
2009 Clinical Cancer Research

Peers

Countries citing papers authored by Axel Hoos

Since Specialization

Citations

This map shows the geographic impact of Axel Hoos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Hoos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Hoos more than expected).

Fields of papers citing papers by Axel Hoos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Axel Hoos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Hoos. The network helps show where Axel Hoos may publish in the future.

Co-authors

The 25 scholars most cited alongside Axel Hoos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Axel Hoos Line = papers co-authored together Axel Hoos links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study Annals of Oncology ·Eric Angevin, Stefanie L. Groenland, Todd M. Bauer, Danny Rischin, 俞雄飞, 晃柳橋, José Trigo, Michael Chisamore, Jafar Sadik Shaik, Fabio Rigat, Fernández-Moya Jésus, Ferreira Tasso Jorge Tavares, Robert Gagnon, Dorothea Tropp, David C. Turner, Sapna Yadavilli, Marc Ballas, Axel Hoos, Michele Maio	2020	2
2	Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma Clinical Cancer Research ·Weiyi Peng, Leila J. Williams, Chunyu Xu, Brenda Melendez, Jodi A. McKenzie, Yuan Chen, Luis Alberto Sánches Bazán, Kui Shin Voo, Rina M. Mbofung, Sara Elizabeth Leahey, Jian Wang, Gregory Lizée, Hussein A. Tawbi, Michael A. Davies, Axel Hoos, James Smothers, Roopa Srinivasan, Elaine Paul, Niranjan Yanamandra, Patrick Hwu	2019	33
3	Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody Annals of Oncology ·Sara Brett, Sapna Yadavilli, Laura Seestaller‐Wehr, Sabyasachi Bhattacharya, Luis Alberto Sánches Bazán, Meixia Bi, Jane E. Willoughby, 洋紀八木, P. Miculan, Luis Martín Hernández, Janine A. Cunningham, J. Jing, Ashleigh Hahn, Giovanny Silva de Oliveira, C Johnston-Peck Aaron, Jing Yu, Daniel Olive, Mark S. Cragg, Patrick A. Mayes, Axel Hoos	2018	1
4	Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial The Lancet Oncology ·Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M. Voorhees, Brandi Reeves, Edward N. Libby, Paul G. Richardson, Larry D. Anderson, Heather J. Sutherland, Kwee Yong, Axel Hoos, M Gorczyca, Soumi Lahiri, Zangdong He, Daren Austin, Joanna Opalinska, Adam D. Cohen	2018	192
5	The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4 Clinical Cancer Research ·Li Liu, Patrick A. Mayes, Stephen D. Eastman, Hong Shi, Sapna Yadavilli, Tianqian Zhang, Jingsong Yang, Laura Seestaller‐Wehr, Shuyun Zhang, Chris Hopson, Lyuben Tsvetkov, Junping Jing, Shu Zhang, James Smothers, Axel Hoos	2015	352
6	AMP-224, a Fusion Protein that Targets PD-1 Annals of Oncology ·all Higashida, Axel Hoos, Solomon Langermann, 이신아, Rena J. May, Andrew Damian Popp	2013	12
7	Advancing the field of cancer immunotherapy OncoImmunology ·Axel Hoos, Sylvia Janetzki, Cedrik M. Britten	2012	4
8	Evolution of end points for cancer immunotherapy trials Annals of Oncology ·Axel Hoos	2012	78
9	Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment Health and Quality of Life Outcomes ·Dennis A. Revicki, Alfons JM van den Eertwegh, Paul Lorigan, Célèste Lebbé, Gerald P. Linette, Christian H. Ottensmeier, Shima Safikhani, Marianne Messina, Axel Hoos, Samuel Wagner, Srividya Kotapati	2012	46
10	Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond Cancer Immunology Immunotherapy ·Cedrik M. Britten, Sylvia Janetzki, Sjoerd H. van der Burg, Christoph Huber, Michael Kalos, James O'Hern, Holden T. Maecker, Cornelis J.M. Melief, Jill O’Donnell-Tormey, Kunle Odunsi, Lloyd J. Old, Graham Pawelec, Bart O. Roep, Pedro Romero, Axel Hoos, Mark M. Davis	2010	38
11	Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium Cancer Immunology Immunotherapy ·(unknown), Cedrik M. Britten, Sylvia Janetzki, Leah Ben‐Porat, Timothy M. Clay, Michael Kalos, Holden T. Maecker, Kunle Odunsi, Michael W. Pride, Lloyd J. Old, Axel Hoos, Pedro Romero	2009	47
12	EFFECT OF DOSE ON EFFICACY AND SAFETY IN IPILIMUMAB-TREATED PATIENTS WITH ADVANCED MELANOMA - RESULTS FROM A PHASE II, RANDOMIZED, DOSE-RANGING STUDY Annals of Oncology ·Célèste Lebbé, Axel Hoos, Kevin M. Chin, Marc Scattergood, Bart Neyns, Gerald P. Linette, Sylvie Négrier, Dirk Schadendorf, Michael Smylie, P. Fabyan	2008	6
13	A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer Cancer Chemotherapy and Pharmacology ·Tomislav Dragovich, David S. Mendelson, Sandra Kurtin, Kelly M. Richardson, Daniel D. Von Hoff, Axel Hoos	2006	106
14	Squamous cell carcinoma–related oncogene is highly expressed in developing, normal, and adenomatous adrenal tissue but not in aggressive adrenocortical carcinomas Surgery ·Inderpal S. Sarkaria, Alexander Stojadinovic, Simon G. Talbot, Axel Hoos, Mária Dudás, Murray F. Brennan, Ronald Ghossein, Bhuvanesh Singh	2004	8
15	Prognostic evaluation and review of immunohistochemically detected disseminated tumor cells in peritumoral lymph nodes of patients with pN0 colorectal cancer International Journal of Colorectal Disease ·Robert Rosenberg, Jan Friederichs, Ralf Gertler, Axel Hoos, James Mueller, Jörg Nährig, H. Nekarda, Joerg-Ruediger Siewert	2004	54
16	Parathyroid neoplasms: Clinical, histopathological, and tissue microarray-based molecular analysis Human Pathology ·Alexander Stojadinovic, Axel Hoos, Aviram Nissan, Mária Dudás, Carlos Cordon‐Cardo, Ashok R. Shaha, Murray F. Brennan, Bhuvanesh Singh, Ronald Ghossein	2003	103
17	Hürthle cell carcinoma: A 60-year experience Annals of Surgical Oncology ·Alexander Stojadinovic, Axel Hoos, Ronald Ghossein, Marshall Urist, Denis H. Y. Leung, Ronald H. Spiro, Jatin P. Shah, Murray F. Brennan, Bhuvanesh Singh, Ashok R. Shaha	2002	64
18	Increased Endocrine Cells in Treated Rectal Adenocarcinomas The American Journal of Surgical Pathology ·Jinru Shia, Satish K. Tickoo, José G. Guillem, Jing Qin, Aviram Nissan, Axel Hoos, Alexander Stojadinovic, Leyo Ruo, W. Douglas Wong, Philip B. Paty, Martin R. Weiser, Bruce D. Minsky, David S. Klimstra	2002	59
19	High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas Cancer ·Axel Hoos, Alexander Stojadinovic, Stephen Mastorides, Zola, Émile, 1840-1902, David Polsky, Charles J. Di Como, Murray F. Brennan, Carlos Cordon‐Cardo	2001	78
20	Desmoid tumors of the head and neck—A clinical study of a rare entity Head & Neck ·Axel Hoos, Jonathan J. Lewis, Marshall Urist, Ashok R. Shaha, William G. Hawkins, Jatin P. Shah, Murray F. Brennan	2000	62

About Axel Hoos

Axel Hoos is a scholar working on Oncology, Immunology, Biotechnology, Hematology and Radiology, Nuclear Medicine and Imaging, having authored 142 papers that have together received 13.4k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (64 papers), CAR-T cell therapy research (45 papers), Immunotherapy and Immune Responses (39 papers), Monoclonal and Polyclonal Antibodies Research (16 papers), Melanoma and MAPK Pathways (12 papers), vaccines and immunoinformatics approaches (9 papers), Cancer Research and Treatments (9 papers) and Multiple Myeloma Research and Treatments (8 papers). The work is most often cited by research in Oncology (9.2k citations), Immunology (4.7k citations), Pulmonary and Respiratory Medicine (2.8k citations), Cancer Research (1.1k citations) and Pathology and Forensic Medicine (1.1k citations). Axel Hoos has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Jedd D. Wolchok, Steven O’Day, Rachel Humphrey, F. Stephen Hodi, Célèste Lebbé, Murray F. Brennan, Carlos Cordon‐Cardo, Michele Maio, Alexander Stojadinovic and Jeffrey S. Weber. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Clinical Cancer Research and Nature Reviews Drug Discovery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact